Vulval and vaginal skin boosters are injectable hyaluronic-acid treatments considered for targeted hydration and tissue-quality support. “Skin booster” is a broad treatment description, so the exact formulation, intended use and anatomical area must be reviewed before treatment.

Hyaluronic acid binds water within tissues. A selected injectable formulation may therefore be used with the aim of supporting local hydration and tissue quality. Product properties and placement affect how it behaves, and the treatment cannot correct every cause of vulval or vaginal dryness.

No injectable procedure is risk-free. Expected reactions can include pain, redness, swelling, bruising, tenderness and temporary bumps. Infection, inflammatory or allergic reactions, lumps or irregularity, and rare vascular injury or tissue damage must also be considered. Risk depends on the product, anatomy, technique and patient factors.

They may be discussed with selected women seeking tissue quality, hydration or comfort support, especially in menopause-related, postpartum or age-related intimate tissue changes. Suitability is confirmed only after consultation and assessment.

This treatment is not suitable for everyone. It may need to be avoided or delayed during pregnancy or breastfeeding, with active infection or uncontrolled inflammation, unexplained bleeding or pain, a lump, ulcer or suspicious skin change, relevant allergy, bleeding or healing concerns, a product-specific contraindication or unrealistic expectations.

They may be discussed after menopause in selected women, but they are not a replacement for established GSM care. Vaginal moisturisers, lubricants, vaginal oestrogen or other menopause treatments may be more appropriate depending on symptoms and medical history.

Randomised and follow-up studies of particular injectable hyaluronic-acid formulations have reported improvement in selected postmenopausal women with vulvovaginal atrophy symptoms. These results do not establish that every skin booster treats every cause of dryness. Diagnosis and established options still need to be considered.

Local comfort measures may be used. Some women experience stinging, pressure or sensitivity during or after treatment. We do not describe injectable intimate treatments as painless.

The treatment involves consultation, suitability assessment, consent, cleaning the area, local comfort measures if appropriate, and careful placement of the skin-booster injectable in the planned vulval and/or vaginal area.

Published protocols vary from a single session to a course. WHC does not apply one schedule to every woman. The number and spacing of sessions depend on the selected product, treatment area, symptoms, clinical plan and response.

Duration varies. A 52-week follow-up study reported sustained changes after one specific cross-linked hyaluronic-acid protocol in selected postmenopausal women, but that result cannot be applied to every product, anatomical area or patient. Effects are not permanent or guaranteed.

Recovery is usually short, but mild redness, swelling, bruising, small bumps, tenderness or sensitivity can occur. You may be advised to avoid intercourse, tampons, swimming, saunas, hot baths or vigorous exercise for a short period.

Sometimes, but only as an assessment-led plan. Skin boosters may be considered alongside established menopause care, PRP, laser, polynucleotides or another treatment, either within a staged pathway or separately. Combination treatment is not automatically better and should not be undertaken simply to intensify the procedure.

PRP uses platelet-rich plasma prepared from your own blood. Skin boosters use a manufactured hyaluronic-acid product. The materials, preparation, evidence, contraindications and treatment objectives are different.

Both may use hyaluronic acid, but G-Shot-style or intimate filler treatment is usually planned for focal projection or volume. A skin booster is planned mainly for hydration and tissue-quality support. Product characteristics, placement and objectives differ.

Vaginal laser and radiofrequency use energy; skin boosters place a hyaluronic-acid material into selected tissue. Their mechanisms, evidence, risks, recovery and suitability differ. None should be presented as universally better.

No. Products differ in formulation, concentration, cross-linking, rheology, intended use and manufacturer instructions. A product used for facial skin quality cannot automatically be assumed suitable for vulval or vaginal tissue.

Evidence is emerging and product-specific. A 2025 multicentre randomised placebo-controlled study assessed one cross-linked hyaluronic-acid gel in postmenopausal vulvovaginal atrophy, with later follow-up reporting changes to 52 weeks. Other studies are small or use different products and protocols. Skin boosters remain outside standard first-line NICE care for GSM.

We advise a doctor face-to-face consultation at £150 before treatment. Treatment/session fees should be checked on the current WHC pricing page because pricing may vary by product, area treated, number of sessions and plan.

Vulval skin boosters are not a standard NHS treatment for menopause-related intimate symptoms. Women with vaginal dryness, pain, bleeding, urinary symptoms or vulval changes should seek appropriate medical assessment and discuss established treatment options.

WHC does not promote or commit to one brand. The doctor selects from suitable products available for UK practice after reviewing current product documentation, quality and regulatory requirements, intended use, anatomical area and individual suitability. You should be told which product is proposed before consent.

They may be discussed after recovery in selected women, but postpartum concerns can involve pelvic-floor change, scar tissue, breastfeeding-related hormone change, infection or pain. Treatment is not undertaken during pregnancy or breastfeeding, and assessment is needed before any later procedure is considered.

Do not stop prescribed HRT or vaginal hormone treatment without medical advice. Your current menopause treatment, vaginal oestrogen, moisturisers, lubricants and other medications should be discussed during consultation.